Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $439,752.00 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,752 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $251.00, for a total value of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at $3,941,955. This represents a 10.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $250.98, for a total value of $422,148.36.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $245.44 on Monday. The company has a fifty day moving average price of $267.01 and a 200 day moving average price of $249.57. The firm has a market cap of $31.66 billion, a PE ratio of -93.68 and a beta of 0.32. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.91 million. During the same period in the prior year, the company earned $1.15 earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was down 33.3% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. JPMorgan Chase & Co. boosted their price objective on shares of Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a research report on Monday, August 26th. Barclays boosted their target price on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Finally, Chardan Capital reiterated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. American Trust bought a new position in Alnylam Pharmaceuticals in the third quarter valued at $309,000. Tidal Investments LLC grew its holdings in shares of Alnylam Pharmaceuticals by 75.1% in the 3rd quarter. Tidal Investments LLC now owns 20,544 shares of the biopharmaceutical company’s stock valued at $5,650,000 after acquiring an additional 8,811 shares in the last quarter. Sanctuary Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 91.8% in the third quarter. Sanctuary Advisors LLC now owns 4,558 shares of the biopharmaceutical company’s stock valued at $1,254,000 after acquiring an additional 2,181 shares during the last quarter. Teachers Retirement System of The State of Kentucky raised its holdings in Alnylam Pharmaceuticals by 4.5% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company’s stock worth $9,547,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Toronto Dominion Bank boosted its position in Alnylam Pharmaceuticals by 27.3% during the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after purchasing an additional 3,315 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.